// App-Quantinova.ai

2818 : An unbiased tumor cell panel profiling method to identify drug-drug interactions reveals synergy between the CDK4 and CDK 6 inhibitor abemaciclib and the Raf dimer and pan-Raf inhibitor LY3009120 in Ras mutant cancers

Researchers

Presenter

  • Xueqian Gong

Principal Investigators

  • Wenjuan Wu

  • Li-Chun Chio

  • Susan Pratt

  • Constance King

  • Yue Webster

  • Maria Jose Lallena

  • Karsten Boehnke

  • Raquel Torres

  • Philip Iversen

  • Christoph Reinhard

  • Shih-Hsun Chen

  • Richard Bechmann

  • Sheng-Bin Peng

  • Sean Buchanan

Medical Centers

  • Eli Lilly and Company, Indianapolis, IN

  • Eli Lilly and Company, Madrid, Spain

  • Eli Lilly and Company, Alcobendas, Spain.

Locations

  • United States

  • Spain

Companies

  • Eli Lilly and Compan

  • EMB Statistical Solu

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Cyclin-dependent kinase 4

Drug/Treatment

  • Abemaciclib

  • LY 3009120

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved